Gilead Sciences Touts Encouraging Data From Real World Studies Of Its Flagship COVID-19 Treatment


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


  • Gilead Sciences Inc (NASDAQ:GILDannounced data from three retrospective real-world Veklury (remdesivir) studies for COVID-19 treatment.
  • The studies demonstrated that initiating Veklury within the first two days of hospital admission can help reduce mortality and hospital readmission rates among all patients hospitalized with COVID-19, regardless of disease severity.
  • A reduction in mortality was also observed in vulnerable populations.
  • Related: WHO Recommends Gilead's COVID-19 Therapy For Severe Disease.
  • Two studies analyzed clinical practice information from the U.S. Premier Healthcare databases of more than 500,000 adult patients hospitalized with COVID-19. 
  • For patients with no documented use of supplemental oxygen at baseline, treatment with Veklury was associated with a 19% lower risk of mortality at Day 28. 
  • Patients on low-flow or high-flow oxygen also had a 21% and 12% lower mortality risk at Day 28, respectively. 
  • Patients on invasive mechanical ventilation/ECMO at baseline had a 26% reduced risk for mortality at Day 28. 
  • These findings were observed throughout all variant periods, including Omicron, in patients who did not require supplemental oxygen and across all levels of supplemental oxygen use.
  • A separate analysis found that hospitalized patients with COVID-19 treated with Veklury were also significantly less likely (27%) to be readmitted within 30 days to the same hospital. 
  • Based on in vitro analyses, Veklury retains potent antiviral activity against recent Omicron subvariants of concern.
  • Price Action: GILD shares are down 0.38% at $84.32 on the last check Wednesday.

27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs